August 21, 2014 - Cysteamine bitartrate, the active ingredient in RP103 by Raptor Pharmaceutical Corp., received the orphan drug designation for HD treatment by the European Medicines Agency (EMA).
Contenuti in "Ricerca"
December 19, 2014 - Auspex Pharmaceutical announces the positive conclusion of the SD-809 molecule clinical trial for the treatment of the corea symptom in Huntington Disease patients.
January 9, 2015- We publish an interesting article on the rihabilitation role on HD presented in the Dicember 13, 2014 HD Conference held in Pontedera (Pisa - Tuscany). The conference was promoted by LIRH Toscana together with AUSL 5 Pisa
May 21, 2014 - Today the firts two European patients rectruited in the phase II clinical trial "Pride-HD" by Ferdinando Squitieri, P.I. and coordinator for Italy.